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Abstract
Purpose: We previously showed that 90% (47 of 52; 95% CI, 0.79 to 0.96) of lung adenocarcinomas from East Asian never-
smokers harbored well-known oncogenic mutations in just four genes: EGFR, HER2, ALK, and KRAS. Here, we sought to
extend these findings to more samples and identify driver alterations in tumors negative for these mutations.
Experimental Design: We have collected and analyzed 202 resected lung adenocarcinomas from never smokers seen at
Fudan University Shanghai Cancer Center. Since mutations were mutually exclusive in the first 52 examined, we determined
the status of EGFR, KRAS, HER2, ALK, and BRAF in stepwise fashion as previously described. Samples negative for mutations in
these 5 genes were subsequently examined for known ROS1 fusions by RT-PCR and direct sequencing.
Results: 152 tumors (75.3%) harbored EGFR mutations, 12 (6%) had HER2 mutations, 10 (5%) had ALK fusions all involving
EML4 as the 59 partner, 4 (2%) had KRAS mutations, and 2 (1%) harbored ROS1 fusions. No BRAF mutation were detected.
Conclusion: The vast majority (176 of 202; 87.1%, 95% CI: 0.82 to 0.91) of lung adenocarcinomas from never smokers harbor
mutant kinases sensitive to available TKIs. Interestingly, patients with EGFR mutant patients tend to be older than those
without EGFR mutations (58.3 Vs 54.3, P=0.016) and patient without any known oncogenic driver tend to be diagnosed at a
younger age (52.3 Vs 57.9, P=0.013). Collectively, these data indicate that the majority of never smokers with lung
adenocarcinoma could benefit from treatment with a specific tyrosine kinase inhibitor.
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Introduction
Lung cancer is the leading cause of cancer-related death
worldwide [1,2]. Although the majority of cases occur in those
with a personal history of tobacco smoke exposure, lung cancer
also occurs in never smokers, defined as individuals who smoked
less than 100 cigarettes in a lifetime. If lung cancer from never
smokers was considered as a separate category, the disease would
rank among seven to nine most common fatal cancers in the
US[3]. While it was reported that up to 30% of lung cancer
patients in East Asia were never smokers, it would rank the fifth
most common malignancies in China as a separate disease[4,5].
Lung cancer in never smokers is clinically distinct from other
subsets of the disease. First, although lung cancer is comprised of
four main histologies including small cell carcinoma, squamous
cell carcinoma, large cell carcinoma, and adenocarcinoma, about
70% of never smokers have adenocarcinoma[6]. Second, women
have higher risk of developing lung cancer than men among never
smokers[3,7]. Third, never smokers comprise a higher percentage
(,30%) of patients with lung cancer in East Asian countries versus
North American and European populations (,10%)[4,6]. Reasons
for this discrepancy are unknown.
At the molecular level, lung cancer in never smokers is also
unique. From genetic analysis of 52 adenocarcinomas samples from
patients who never smoked, we previously showed that approxi-
mately 90% of samples harbor mutually exclusive driver alterations
in just four genes: EGFR, KRAS, HER2,a n dALK[8]. By contrast,
only ,40% of cases of non-small cell lung cancer (NSCLC, which
includes squamous cell carcinoma, large cell carcinoma, and
adenocarcinoma histology) would harbor such mutations.
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smoker tumor samples besides the 52 samples previously published
for detection of known driver mutations including EGFR, KRAS,
HER2, BRAF, and EML4-ALK alterations [8]. Furthermore, we
screened ‘pan-negative’ samples for the presence of ROS1 fusions.
ROS1 is the human homolog of the avian sarcoma virus UR2
transforming gene v-ros and encodes a receptor tyrosine kinase
(RTK) of the insulin receptor family. Activating ROS1 fusions
(involving the FIG gene) were previously found in glioblastoma [9]
and more recently in lung cancer [10]. We chose to focus first on
ROS1 because cell lines harboring ROS1 fusions are sensitive to the
tyrosine kinase inhibitor, crizotinib (Bergethon, Pao, Ji, Chen,
Iafrate, et al, submitted), making it another potentially targetable
mutant kinase in the disease. This study will hopefully provide
important insights into molecular defects and identify therapeutic
targets in never smoker patients with lung adenocarcinomas.
Materials and Methods
Patients and tissues
Primary tumor samples were obtained from 1103 consecutive
patients who underwent potentially curative pulmonary resection
at the Fudan University Shanghai Cancer Centre from Oct 2007
through Sep 2010. This study was approved by the Institutional
Review Board of the Fudan University Shanghai Cancer Center,
Shanghai, China. All participants gave written informed consent.
We further collected 150 never smoker tumor samples besides the
52 samples that have been published [8]. A total of 202 patients
were enrolled in this specific study based upon the following
criteria: they are all never smokers (defined as smoked less than
100 cigarettes in their lifetime), they had a pathologic diagnosis of
lung adenocarcinoma, their tumor sample contained a minimum
of 50% tumor cells as determined by study pathologists, they did
not receive neoadjuvant chemotherapy, and they had sufficient
tissue for molecular analysis.
RNA extraction and mutational analysis
All mutational analyses were performed in China. Frozen tissues
were grossly dissected into TRIZOL (Invitrogen Inc.) for RNA
extraction following standard protocols. Total RNA samples were
reverse transcribed into single-stranded cDNA using RevertAid
TM
First Strand cDNA Synthesis Kit (Fermentas, EU).
EGFR (exons 18–22), HER2 (exons 18 to 21), KRAS (exons 2 to
3), and BRAF (exons 11 to 15) were PCR amplified using cDNA
and directly sequenced. For detection of EML4-ALK fusions,
primers were designed to amplify all known fusion variants using
cDNA. The forward primers were EML4 E2F (59-TGATGTTTT-
GAGGCGTCTTG-39), EML4 E13F (59-AGATCGCCTGTCA-
GCTCTTG-39), and EML4 E18F (59-TTAGCATTCTTGGG-
GAATGG-39), and the reverse primer ALK E20R was (59-
TGCCAGCAAAGCAGTAGTTG-39). Primers used to detect
fusions between ALK and KIF5B or TFG were as previously
reported [11,12]. For detection of CD74-ROS1 and SLC34A2-
ROS1 fusions, the forward primers were CD74 E5F (59-CCTGA-
GACACCTTAAGAACACCA-39) and SLC34A2 E4F (59-TCG-
GATTTCTCTACTTTTTCGTG-39). The reverse ROS1 primer
was E34R (59-TGAAACTTGTTTCTGGTATCCAA-39).
Multiplex PCR analysis was done with KOD plus DNA
polymerase (Toyobo, Osaka, Japan). The program to detect ALK
fusions was : 94uC 5 minutes; 94uC 30 seconds, 63uC 30 seconds,
68uC 1 minute, 35 cycles; 68uC 10 minutes. The program to
detect ROS1 fusions was: 94uC 5 minutes; 98uC 10 seconds, 62uC
30 seconds, 68uC 15 seconds, 35 cycles; 68uC 10 minutes. PCR
products were directly sequenced in both forward and reverse
directions. All mutations were verified by analysis of an
independent PCR isolate.
Real-time PCR quantification
The level of ROS1 mRNA was determined using PlatinumH
SYBRH Green qPCR SuperMix-UDG (Invitrogen, CA, USA). The
primers for real-time PCR were ROS1-qPCR-F (59-CAAGAACC-
CGACCAAAGACCTAC-39) and ROS1-qPCR-R (59-CAAATCA-
CATCGCCATCTTCACC-39). The results were analyzed and
expressed as relative mRNA expression of CT (Threshold Cycle)
value, which was then converted to fold changes.
Statistical analysis
Associations between mutations and clinical and biological
characteristics were analyzed by x
2 or Fisher’s exact test. All data
were analyzed using the Statistical Package for the Social Sciences
Version 16.0 Software (SPSS Inc., Chicago, IL). The two-sided
significance level was set at p,0.05.
Results
Patient Characteristics
From Oct 2007 to Sep 2010, we consecutively collected a total
of 452 resected lung adenocarcinomas. All patients were Chinese.
Interestingly, there were 285 from never smokers while only 167
were from smokers,highlighting a predominant percentage
(63.1%) of never smokers in this specific subtype of lung cancer.
202 lung adenocarcinomas from never smokers met eligibility for
this study. The median age at diagnosis was 57.3 years (Table 1).
The number of patients in stages I-IV was 113, 21, 62 and 6,
respectively. 43 tumors were from males and 159 from females. No
differences were observed in age, stage, or degree of tumor
differentiation between males and females.
EGFR mutation status
75.3% (152/202) of tumors were found to harbor EGFR kinase
domain mutations (Figure 1). Among these, 77 were deletions in
exon 19 and 59 were L858R missense changes. Other alterations
included 7 exon 20 insertions and 4 exon 18 G719X mutations. 2
samples from patients without previous chemotherapy or TKI
Table 1. Clinical Characteristics of Never Smokers With Lung
Adenocarcinomas.
Sex
Characteristics Total Male Female P
No. of patients 202 43 159
Age, years 57.3 59.9 56.6 .061
SD 10.1 11 9.8
Clinical Stage
I 113 18 95 .058
II 21 7 14
III 62 15 47
I V 633
Differentiation
Well 38 8 30 .160
Moderate 111 19 92
Poor 53 16 37
doi:10.1371/journal.pone.0028204.t001
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Other EGFR mutations included L816Q, I768S, E709K, and
K757M.
Tumors from 76.7% (122/159) of female never smokers
harbored EGFR kinase domain mutations. A comparable EGFR
mutation rate (69.8%, 30/43) was found in male never smokers
(P=0.348). This confirmed our previous study [13] showing no
significant difference in the frequency of EGFR mutations between
men and women with lung adenocarcinoma who never smoked.
The average age at diagnosis between patients with EGFR mutant
and wild-type tumors was 58.3 and 54.3 years, respectively
(P=0.016), showing that patients with EGFR mutant patients tend
to be older than those without EGFR mutations. The EGFR
mutation rate in well, moderate and poorly differentiated tumors
was 86.8%, 75.7% and 66% respectively (P=0.075) (Table 2).
There were no statistically significant differences among subtypes
of EGFR mutation and the analyzed clinicopathological features
(Table 3).
HER2, KRAS, BRAF, and ALK alterations
5.9% (12/202) of samples had HER2 kinase domain mutations,
among which 11 had exon 20 insertions and 1 had an L755P point
mutation. EML4-ALK fusions were found in 5% (10/202) of
samples, involving EML4 exons 13, 20, and 6 (V1, V2 and V3a/b
variants). No KIF5B-ALK or TFG-ALK fusions were detected. Four
samples (2%) had a KRAS mutation, including two G12V and two
G12D mutations, respectively. No mutations were found in BRAF
(Figure 1). Clinical characteristics associated with these different
oncogenic driver mutations are shown in Table 4.
Figure 1. Spectrum of oncogenic driver mutations in lung adenocarcinomas from never smokers. From 202 tumors, 75.3% (152/202)
harbored EGFR kinase domain mutations, 5.9% (12/202) HER2 mutations, 5.0% (10/202) ALK fusions, and 2% (4/202) KRAS mutations, 1% (2/202) of
tumors harbor ROS1 fusion. There are 10.9% (22/202) with unknown oncogenic driver mutations.
doi:10.1371/journal.pone.0028204.g001
Table 2. Association between EGFR tyrosine kinase mutations
and clinical pathological features.
Characteristics Total Mutant Wild type P
Age, years 57.3 58.3 54.3 .016
SD 10.1 9.8 10.4
Gender
Male 43 30 13 .348
Female 159 122 37
Clinical Stage
I 113 87 26 .831
II 21 16 5
III 62 44 18
IV 6 5 1
Differentiation
Well 38 33 5 .075
Moderate 111 84 27
Poor 53 35 18
doi:10.1371/journal.pone.0028204.t002
Table 3. Correlation Between EGFR Mutation Subtypes and
Clinical Pathological Features.
Subtypes of EGFR mutation
Characteristics Total Exon 19 deletion L858R Others P
Age, years 58.3 57.1 60.6 55.4 0.056
SD 9.8 10.2 8.9 10.4
Gender
Male 13 13 4 0.608
Female 64 46 12
Clinical Stage
I 42 36 9 0.899
II 10 5 1
III 23 16 5
IV 2 2 1
Differentiation
Well 11 15 7 0.073
Moderate 46 30 8
Poor 20 14 1
doi:10.1371/journal.pone.0028204.t003
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1% (2/202) of samples had CD74-ROS1 fusions (Figure 2A).
No fusions involving SLC34A2 were detected. Both patients with
ROS1 rearrangements were female and diagnosed with stage III
disease, and both harbored the previously described CD74-ROS1
fusion involving exon 34 of ROS1 fused to exon 6 of CD74
(Figure 2B). Interestingly, one of the samples (No.136) had two
types of CD74-ROS1 fusions: exon 32 or exon 34 of ROS1 fused to
exon 6 of CD74 (Fig. 2C). Both fusions were in-frame and retained
the transmembrane region of ROS1, which may be different
splicing products produced from the same translocation event
similar to SLC34A2-ROS1 fusions previously found in HCC78 cells
[10]. To test if the high ROS1 expression is associated with the
ROS1 fusion, we have performed the Q-PCR experiment in 24
samples including the 2 ROS1-fusion positive samples, 3 EGFR
mutated samples, 2 KRAS mutated samples, 2 ALK fusion positive
samples, 1 HER2 mutated sample and 14 pan-negative samples
defined as without above driver mutations. Interestingly, both
ROS1-fusion positive samples did show relative high ROS1
expression (Figure 3). However, other samples with either ALK
fusion or EGFR mutations or without any known oncogenic drivers
also showed comparable expression of ROS1 (Figure 3),
indicating that the ROS1 mRNA level may not be as an good
indicator for the ROS1 fusion.
Table 4. Association Between Driver Mutations and Age and Gender in Lung Adenocarcinoma From Never Smokers.
HER2 EML4-ALK KRAS ROS1
Characteristics Mutant Wild type P Mutant Wild type P Mutant Wild type P Mutant Wild type P
Age, years 52.8 57.6 0.107 59.3 57.3 0.540 62.0 57.3 0.359 46.5 57.5 0.128
SD 5.4 10.3 9.8 10.2 3.4 10.2 2.1 10.2
Gender
Male 1 42 0.467 4 39 0.228 3 40 0.032 0 43 1.000
Female 11 148 6 150 1 155 2 154
doi:10.1371/journal.pone.0028204.t004
Figure 2. Detection of CD74-ROS1 fusions in lung adenocarcinomas from never smokers. (A) Agarose gel electrophoresis analysis of RT-
PCR products for CD74-ROS1 fusions. E32, CD74-ROS1 exon 32 fusion; E34, CD74-ROS1 exon 34 fusion. (B) Sequencing of RT-PCR product from a
tumor (No.72) identified a fusion of CD74 exon 6 to ROS1 exon 34. (C) Sequencing of RT-PCR product from a tumor (No.136) identified a fusion of
CD74 exon 6 to both ROS1 exon 32 and exon 34.
doi:10.1371/journal.pone.0028204.g002
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Despite identification of ROS1 rearrangements, still 10.9% (22
of 202) samples had no identifiable driver mutation (Figure 1).
These data are consistent with our previously published study[8].
Interestingly, further comparative analyses showed that patients
without oncogenic driver mutation tend to be diagnosed at a
younger age than those with known oncogenic drivers (52.27 Vs
57.93, P=0.013) (Table 5).
Discussion
During the past decade, a wealth of data from genomic[14],
expression[15], mutational[16], and proteomic profiling stud-
ies[10] have led to the identification of multiple molecularly
distinct subsets of non-small cell lung cancer (NSCLC). Based
upon these findings, one of the most promising treatment strategies
now involves the subdivision of NSCLC histologies into clinically
relevant molecular subsets, using a classification schema based
upon specific ‘driver mutations’. Major recurrent mutations in
lung adenocarcinoma have been found to occur in EGFR, KRAS,
HER2, BRAF, ALK and ROS1.
In our previous study, approximately 90% of lung adenocar-
cinomas from never smokers harbor known oncogenic mutations
in just 4 genes of EGFR, KRAS, HER2, EML4-ALK[8]. Here we
comprehensively analyzed all the known oncogenic drivers up to
date including all known types of ALK fusions besides EML4-ALK
and ROS1 fusions and expanded the sample size. We show that
89.1% of samples harbor known oncogenic driver mutations,
consistent with our previous report[8]. In the present study, EGFR
kinase domain mutations were found in 75.3% of samples. EGFR
kinase domain mutations are more common in elder patients
(P=0.016), consistent with previous studies[17].
The mutation spectrum including EGFR, HER2, KRAS, EML4-
ALK in this study shows similar proportions as previously
described[8]. In an attempt to provide a more comprehensive
map of oncogenic drivers, we have examined other types of ALK
fusions, such as KIF5B-ALK and TFG-ALK. However, no tumor
positive for these two ALK fusions was found. We have identified
12 samples with HER2 kinase domain mutations, including 11
exon 20 insertions and 1 L755P point mutation. A previous study
showed that lung adenocarcinoma patients harboring HER2 exon
20 insertion responded dramatically to Trastuzumab, a monoclo-
nal antibody to HER2[18]. Pan-ErbB family inhibitors such as
Neratinib and BIBW2992[19,20], under clinical trials to overcome
EGFR T790M mutation, may also be used in patients harboring
HER2 mutations. Except for KRAS, all the other oncogenic driver
mutations have targeted agents being used in clinic or under
clinical trials.
ROS1 fusion is recognized as a new oncogenic driver [10]. Here
we found about 1% of samples harbored CD74-ROS1 fusion.
Interestingly, there is one sample with two forms of ROS1 fusion,
which may be derived from the same rearrangement due to
alternative splicing mechanism as previously reported[10]. How-
ever, it remains unknown why one tumor harbors two forms of
fusion and if there is any synergy between them. ROS1 fusion has
been shown to contribute to the formation of lung adenocarcino-
ma [10]. Knockdown of ROS1 in the lung cancer cell line HCC78
which has SLC34A2-ROS1 fusion promotes apoptosis [10],
indicating ROS1 fusion is important for cell survival. This validates
ROS1 as a good target for clinical treatment. Lung cancer cell line
HCC78 positive for ROS1 fusion is sensitive to the tyrosine kinase
inhibitor, crizotinib (Bergethon, Pao, Ji, Chen, Iafrate, et al,
submitted), indicating that ROS1 fusion is another potentially
targetable mutant kinase for lung cancer.
In summary, we have expanded and extended our previous
study and examined all known oncogenic driver mutations up to
date in lung adenocarcinomas from a large cohort of never
smokers. Most of the patients could be classified to a certain type
according to oncogenic driver mutations. Except for KRAS, all
oncogenic drivers can be effectively targeted in clinic, highlighting
the importance of molecular classification of lung adenocarcinoma
in never smokers. Interestingly, patients without any oncogenic
driver mutation tend to be diagnosed at a younger age. Although
we do not have an explanation yet, we are now studying these
‘Pan-negative’ samples using whole exome sequencing in a hope to
identify certain novel oncogenic drivers. Our study suggest that
most lung adenocarcinoma patients who never smoked could
potentially benefit from personalized targeted therapy.
Figure 3. Detection of ROS1 mRNA levels in lung adenocarci-
nomas from never smokers either with indicated oncogenic
driver mutations or negative for all known oncogenic driver
mutations.
doi:10.1371/journal.pone.0028204.g003
Table 5. Comparison of clinical Characteristics of patients
with or without known driver mutations.
With known
driver mutations
Without known
driver mutations P value
Age, years 57.9 52.3 0.013
SD 9.6 12.7
Gender
Male 38 5 0.789
Female 142 17
Clinical Stage
I–II 118 16 0.502
III–IV 62 6
Differentiation
Well 36 2 0.441
Moderate 98 13
Poor 46 7
doi:10.1371/journal.pone.0028204.t005
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